Signaturefd, LLC Beam Therapeutics Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 574 shares of BEAM stock, worth $14,516. This represents 0.0% of its overall portfolio holdings.

Number of Shares

574

Previous 722 20.5%

Holding current value

$14,516

Previous $16,000 12.5%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	SELL	$22.57 - $33.14 $3,340 - $4,904	-148 Reduced 20.5%	574 $14,000
Q2 2024 Jul 29, 2024	SELL	$21.22 - $32.66 $7,342 - $11,300	-346 Reduced 32.4%	722 $16,000
Q1 2024 May 03, 2024	BUY	$23.46 - $45.07 $1,102 - $2,118	47 Added 4.6%	1,068 $35,000
Q4 2023 Jan 31, 2024	SELL	$17.69 - $30.76 $29,383 - $51,092	-1,661 Reduced 61.93%	1,021 $27,000
Q3 2023 Nov 03, 2023	BUY	$23.01 - $32.46 $60,401 - $85,207	2,625 Added 4605.26%	2,682 $64,000
Q2 2023 Aug 01, 2023	BUY	$29.32 - $35.99 $1,466 - $1,799	50 Added 714.29%	57 $1,000
Q1 2023 Apr 28, 2023	SELL	$30.15 - $48.79 $4,311 - $6,976	-143 Reduced 95.33%	7 $0
Q4 2022 Jan 27, 2023	BUY	$36.73 - $51.6 $734 - $1,032	20 Added 15.38%	150 $5,000
Q2 2022 Aug 10, 2022	SELL	$29.86 - $62.36 $328 - $685	-11 Reduced 7.8%	130 $5,000
Q1 2022 May 02, 2022	BUY	$53.73 - $82.16 $3,492 - $5,340	65 Added 85.53%	141 $8,000
Q4 2021 Jan 25, 2022	SELL	$68.02 - $99.06 $7,074 - $10,302	-104 Reduced 57.78%	76 $6,000
Q3 2021 Oct 28, 2021	BUY	$84.37 - $133.6 $4,387 - $6,947	52 Added 40.63%	180 $16,000
Q2 2021 Jul 26, 2021	BUY	$64.12 - $128.71 $8,207 - $16,474	128 New	128 $16,000

Others Institutions Holding BEAM

# of Institutions

236

Shares Held

75.2M

Call Options Held

438K

Put Options Held

232K

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account